指南与共识食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病消化内镜

质子泵抑制剂治疗下仍有难治性反流样症状患者的管理:基于证据的共识声明

Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.
指南 / 共识 · Aliment Pharmacol Ther · 2024-12-30

该共识由国际食管炎分类工作组制定,针对质子泵抑制剂治疗下仍有难治性反流样症状或难治性胃食管反流病的患者,采用PICO问题、系统综述和GRADE方法形成17条声明,其中13条达成共识。建议诊断策略包括内镜、动态反流监测和食管测压,不建议在已接受8周每日两次PPI治疗的患者中增加PPI剂量,可考虑辅助藻酸盐或抗酸剂治疗。

要点

  • 对难治性反流样症状,建议诊断策略包括内镜、动态反流监测和食管测压。
  • 已接受8周每日两次PPI治疗者,建议不增加PPI剂量(弱推荐)。
  • 可考虑辅助藻酸盐或抗酸剂治疗;促动力药、TLESR抑制剂或胆汁酸螯合剂作用有限。

核心结论

  • 难治性反流样症状的管理应个体化,基于共享决策讨论诊断性检查在确认或排除GERD以优化治疗中的作用。
  • 无客观确认GERD时,不应进行抗反流手术。

研究设计与样本

  • 由国际食管炎分类工作组制定共识,指导委员会提出PICO问题,方法学家进行系统综述,采用GRADE方法评级证据质量和推荐强度。
  • 17条诊断与管理声明中13条达成共识。

主要发现

  • 对难治性反流样症状,建议的诊断策略包括内镜、动态反流监测和食管测压。
  • 工作组未就食管活检的作用或反流监测中反流-症状关联性的应用达成共识。
  • 对已接受8周每日两次PPI治疗的患者,建议不增加PPI剂量(弱推荐)。
  • 建议辅助藻酸盐或抗酸剂治疗(弱推荐);对辅助促动力药的作用未达成共识。
  • 辅助TLESR抑制剂或胆汁酸螯合剂作用有限;无客观证实GERD时不应进行内镜或外科抗反流手术。

关键数值与推荐

  • 对已接受8周每日两次PPI治疗的患者,建议不增加PPI剂量(弱推荐)。
  • 建议辅助藻酸盐或抗酸剂治疗(弱推荐)。
  • 无客观证实GERD时,不应进行内镜或外科抗反流手术。

临床怎么用

  • 对难治性反流样症状患者,可考虑内镜、动态反流监测和食管测压以确认或排除GERD。
  • 已接受8周每日两次PPI治疗者,建议不增加PPI剂量(弱推荐)。
  • 可考虑辅助藻酸盐或抗酸剂治疗(弱推荐)。
  • 无客观证实GERD时,不应进行内镜或外科抗反流手术。
  • 管理应个体化,基于共享决策讨论诊断性检查的作用。

局限性

  • 17条声明中仅13条达成共识,未就食管活检的作用或反流监测中反流-症状关联性的应用达成共识。
  • 未就辅助促动力药的作用达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients diagnosed with gastro-oesophageal reflux disease (GERD) have persistent symptoms despite proton pump inhibitor (PPI) therapy. AIMS: The aim of this consensus is to provide evidence-based statements to guide clinicians caring for patients with refractory reflux-like symptoms (rRLS) or refractory GERD. METHODS: This consensus was developed by the International Working Group for the Classification of Oesophagitis. The steering committee developed specific PICO questions pertaining to the management of PPI rRLS. Methodologists conducted systematic reviews of the literature. The quality of evidence and strength of recommendations were rated using the GRADE approach. RESULTS: Consensus was reached on 13 of 17 statements on diagnosis and management. For rRLS, suggested diagnostic strategies included endoscopy, ambulatory reflux testing and oesophageal manometry. The group did not reach consensus on the role of oesophageal biopsies or the use of reflux-symptom association in patients undergoing reflux testing. The group suggested against increasing the PPI dose in patients who had received 8 weeks of a twice-daily PPI. Adjunctive alginate or antacid therapy was suggested. There was no consensus on the role of adjunctive prokinetics. There was little role for adjunctive transient lower oesophageal sphincter relaxation (TLESR) inhibitors or bile acid sequestrants. Endoscopic or surgical anti-reflux procedures should not be performed in patients with rRLS in the absence of objectively confirmed GERD. CONCLUSIONS: The management of rRLS should be personalised, based on shared decision-making regarding the role of diagnostic testing to confirm or rule out GERD as a basis for treatment optimisation. Anti-reflux procedures should not be performed without objective confirmation of GERD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Armstrong D, Hungin AP, Kahrilas PJ, et al. Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements. Aliment Pharmacol Ther. 2024. PMID: 39740235. doi:10.1111/apt.18420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。